Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture

被引：45

作者：

Gabel, D

Preusse, D

Haritz, D

Grochulla, F

Haselsberger, K

Fankhauser, H

Ceberg, C

Peters, HD

Klotz, U

机构：

[1] ZENT KRANKENHAUS ST JURGENSTR, NEUROL CLIN, BREMEN, GERMANY

[2] KARL FRANZENS UNIV GRAZ, NEUROL CLIN, GRAZ, AUSTRIA

[3] CHU VAUDOIS, SERV NEUROCHIRURG, CH-1011 LAUSANNE, SWITZERLAND

[4] UNIV LUND HOSP, DEPT RADIOPHYS, S-22185 LUND, SWEDEN

[5] DR MARGARETE FISCHER BOSCH INST CLIN PHARMACOL, D-7000 STUTTGART, GERMANY

来源：

ACTA NEUROCHIRURGICA | 1997年 / 139卷 / 07期

关键词：

boron neutron capture therapy; BSH; glioma;

D O I：

10.1007/BF01411994

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated. in preparation for a Phase I clinical trial of boron neutron capture therapy. BSI-I was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.

引用

页码：606 / 612

页数：7

共 18 条

[1] PERFORMANCE OF SULFHYDRYL BORON HYDRIDE IN PATIENTS WITH GRADE-III AND GRADE-IV ASTROCYTOMA - A BASIS FOR BORON NEUTRON-CAPTURE THERAPY [J].